ArticleAmerican journal of translational research2025
Correlation between β2-microglobulin level and risk of cardiovascular events and prognosis in hemodialysis patients.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to investigate the effect of β2-microgolobulin (β2-MG) on the occurrence of cardiovascular events (CVE) in hemodialysis patients and its relationship with prognosis.
methodsIn this retrospective study, we included 102 hemodialysis patients treated at Jinan People's Hospital Affiliated with Shandong First Medical University from September 2020 to January 2023. Clinical and follow-up data were collected. Logistic regression was used to evaluate the relationship between β2-MG and CVEs, while Cox proportional hazards regression analysis was used to assess the possible correlation between β2-MG and prognosis.
resultsCVEs occurred in 41 of the 102 patients (40.20%). Of the patients, 72 patients survived, and 30 patients died, with an average survival time of 22.47±7.41 months (range: 7-38 months). Univariate analysis revealed no significant differences in age, albumin, serum soluble growth stimulating expression gene 2 protein (ST2), β2-MG, or urea clearance index (Kt/V) between the CVE group and the non-CVE group, nor between the death and survival groups (
conclusionElevated β2-MG level is an independent risk factor for CVEs and mortality in hemodialysis patients, serving as an effective indicator for predicting the occurrence and prognosis of these outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.